Chimerix is a biopharmaceutical company which develop medicines for lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program ONC201, is in development for H3 K27M-mutant glioma. Chimerix is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $0.32M |
| Net Income (Most Recent Fiscal Year) | $-82.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1410.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.35 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -52574.85% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -50.78% |
| Return on Assets (Trailing 12 Months) | -44.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.33 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.33 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.94 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 89.94M |
| Free Float | 78.15M |
| Market Capitalization | $456.88M |
| Average Volume (Last 20 Days) | 1.63M |
| Beta (Past 60 Months) | 0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 45.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |